Lumasiran sodium - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for lumasiran sodium and what is the scope of patent protection?
Lumasiran sodium
is the generic ingredient in one branded drug marketed by Alnylam Pharms Inc and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Lumasiran sodium has one hundred and seventy-nine patent family members in forty-three countries.
One supplier is listed for this compound.
Summary for lumasiran sodium
International Patents: | 179 |
US Patents: | 14 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for lumasiran sodium |
DailyMed Link: | lumasiran sodium at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for lumasiran sodium
Generic Entry Date for lumasiran sodium*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for lumasiran sodium
US Patents and Regulatory Information for lumasiran sodium
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | 10,131,907 | ⤷ Try for Free | Y | Y | ⤷ Try for Free | ||
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | 11,060,093 | ⤷ Try for Free | Y | Y | ⤷ Try for Free | ||
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | 10,487,330 | ⤷ Try for Free | Y | Y | ⤷ Try for Free | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for lumasiran sodium
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 2229186 | CONJUGUÉS GLUCIDIQUES UTILISÉS EN TANT QU'AGENTS D'ADMINISTRATION POUR DES OLIGONUCLÉOTIDES (CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES) | ⤷ Try for Free |
Mexico | 2024005653 | AGENTES DE ACIDO RIBONUCLEICO (ARN) DE CADENA DOBLE MODIFICADOS. (MODIFIED DOUBLE-STRANDED RNA AGENTS.) | ⤷ Try for Free |
Australia | 2021201953 | Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (HAO1) By Double-Stranded RNA | ⤷ Try for Free |
Japan | 6850827 | ⤷ Try for Free | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for lumasiran sodium
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3204015 | LUC00252 | Luxembourg | ⤷ Try for Free | PRODUCT NAME: LUMASIRAN SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/20/1496 20201123 |
3581654 | 122021000053 | Germany | ⤷ Try for Free | PRODUCT NAME: LUMASIRAN; REGISTRATION NO/DATE: EU/1/20/1496 20201119 |
3581654 | PA2021008 | Lithuania | ⤷ Try for Free | PRODUCT NAME: LUMASIRANAS; REGISTRATION NO/DATE: EU/1/20/1496 20201119 |
3204015 | 301167 | Netherlands | ⤷ Try for Free | PRODUCT NAME: LUMASIRAN, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/20/1496 20201123 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for Lumasiran Sodium
More… ↓